Literature DB >> 7852412

CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes.

A J Hoogewerf1, J W Leone, I M Reardon, W J Howe, D Asa, R L Heinrikson, S R Ledbetter.   

Abstract

Heparan sulfate proteoglycans at cell surfaces or in extracellular matrices bind diverse molecules, including growth factors and cytokines, and it is believed that the activities of these molecules may be regulated by the metabolism of heparan sulfate. In this study, purification of a heparan sulfate-degrading enzyme from human platelets led to the discovery that the enzymatic activity residues in at least two members of the platelet basic protein (PBP) family known as connective tissue activating peptide-III (CTAP-III) and neutrophil activating peptide-2. PBP and its N-truncated derivatives, CTAP-III and neutrophil activating peptide-2, are CXC chemokines, a group of molecules involved in inflammation and wound healing. SDS-polyacrylamide gel electrophoresis analysis of the purified heparanase resulted in a single broad band at 8-10 kDa, the known molecular weight of PBP and its truncated derivatives. Gel filtration chromatography of heparanase resulted in peaks of activity corresponding to monomers, dimers, and tetramers; these higher order aggregates are known to form among the chemokines. N-terminal sequence analysis of the same preparation indicated that only PBP and truncated derivatives were present, and commercial CTAP-III from three suppliers had heparanase activity. Antisera produced in animals immunized with a C-terminal synthetic peptide of PBP inhibited heparanase activity by 95%, compared with activity of the purified enzyme in the presence of the preimmune sera. The synthetic peptide also inhibited heparanase by 95% at 250 microM, compared to the 33% inhibition of heparanase activity by two other peptides. The enzyme was determined to be an endoglucosaminidase, and it degraded both heparin and heparan sulfate with optimal activity at pH 5.8. Chromatofocusing of the purified heparanase resulted in two protein peaks: an inactive peak at pI7.3, and an active peak at pI 4.8-5.1. Sequence analysis showed that the two peaks contained identical protein, suggesting that a post-translational modification activates the enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852412     DOI: 10.1074/jbc.270.7.3268

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Characterization of a novel intracellular heparanase that has a FERM domain.

Authors:  Karen J Bame; Indumati Venkatesan; Jean Dehdashti; Jeffrey McFarlane; Rebecca Burfeind
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

2.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix.

Authors:  R Hershkoviz; H Schor; A Ariel; I Hecht; I R Cohen; O Lider; L Cahalon
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

4.  Monocyte-derived CXCL7 peptides in the marrow microenvironment.

Authors:  Manoj M Pillai; Mineo Iwata; Norihiro Awaya; Lynn Graf; Beverly Torok-Storb
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

5.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

6.  Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients.

Authors:  Gina Lee; Brian K Gardner; David A Elashoff; Colleen M Purcell; Harpavan S Sandha; Jenny T Mao; Kostyantyn Krysan; Jay M Lee; Steven M Dubinett
Journal:  Am J Transl Res       Date:  2011-04-02       Impact factor: 4.060

7.  The molecular and cellular basis of exostosis formation in hereditary multiple exostoses.

Authors:  Meirav Trebicz-Geffen; Dror Robinson; Zoharia Evron; Tova Glaser; Mati Fridkin; Yehuda Kollander; Israel Vlodavsky; Neta Ilan; Kit Fong Law; Kathryn S E Cheah; Danny Chan; Haim Werner; Zvi Nevo
Journal:  Int J Exp Pathol       Date:  2008-04-30       Impact factor: 1.925

Review 8.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

9.  CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells.

Authors:  Minghuan Yu; Richard Berk; Mary Ann Kosir
Journal:  J Oncol       Date:  2010-06-22       Impact factor: 4.375

10.  Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases.

Authors:  K J Bame; A Hassall; C Sanderson; I Venkatesan; C Sun
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.